Related Experiment Videos
Heart failure and endothelin receptor antagonists.
1Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Trends in Pharmacological Sciences
|June 4, 1999
Summary
Endothelin-1 is elevated in heart failure. Blocking endothelin receptors with an antagonist improves survival and cardiac function in animal models, suggesting a new therapeutic target.
Area of Science:
- Cardiovascular Biology
- Pharmacology
- Heart Failure Research
Background:
- Endothelin-1 (ET-1) is produced by cardiac myocytes and vascular endothelial cells.
- ET-1 increases cardiac and vascular smooth muscle contractility and causes myocardial hypertrophy and cellular injury.
- ET-1 production is significantly elevated in the failing heart.
Purpose of the Study:
- To evaluate the therapeutic potential of endothelin receptor antagonists (ERAs) for heart failure treatment.
- To investigate the long-term effects of ERAs on survival and cardiac function in heart failure models.
Main Methods:
- Review of evidence on endothelin receptor antagonist efficacy.
- Analysis of animal studies (rat, hamster) with chronic heart failure treated with ERAs.
Main Results:
- Long-term ERA treatment significantly improved survival rates in animal models of chronic heart failure.
- Beneficial effects included amelioration of left ventricular dysfunction.
- The myocardial endothelin system is implicated in heart failure pathophysiology.
Conclusions:
- Endothelin receptor antagonists show promise as a novel therapeutic strategy for heart failure.
- Targeting the myocardial endothelin system offers a new avenue for heart failure intervention.